Cargando…

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials

Precision medicine in oncology promises the matching of genomic, molecular, and clinical data with underlying mechanisms of a range of novel anticancer therapeutics to develop more rational and effective antitumor strategies in a timely manner. However, despite the remarkable progress made in the un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez, Juanita, Harris, Sam, Roda, Desam, Yap, Timothy A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648610/ https://www.ncbi.nlm.nih.gov/pubmed/26609214 http://dx.doi.org/10.4137/TOG.S30533

Ejemplares similares

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach
por: Coleman, Niamh, et al.
Publicado: (2018)

Strategies for modern biomarker and drug development in oncology
por: Smith, Alan D, et al.
Publicado: (2014)

Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
por: Paliard, Xavier, et al.
Publicado: (2019)

Combining targeted therapeutics in the era of precision medicine
por: Papadatos-Pastos, D, et al.
Publicado: (2015)

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017)

Personalized immunotherapy in cancer precision medicine
por: Kiyotani, Kazuma, et al.
Publicado: (2021)

Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies
por: Yin, Jun, et al.
Publicado: (2016)

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
por: Yokota, Tomoya, et al.
Publicado: (2018)

Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
por: Su, Mack Y., et al.
Publicado: (2016)

Immunotherapy in cervical cancer: the advent of precision medicine
por: De Felice, Francesca, et al.
Publicado: (2020)

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre
por: O’Carrigan, Brent, et al.
Publicado: (2018)

Allergen Immunotherapy (AIT): a prototype of Precision Medicine
por: Canonica, GW, et al.
Publicado: (2015)

AIT (allergen immunotherapy): a model for the “precision medicine”
por: Passalacqua, Giovanni, et al.
Publicado: (2015)

Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
por: Nagayama, Satoshi, et al.
Publicado: (2021)

Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers
por: Esposito, Andrea, et al.
Publicado: (2022)

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
por: Tiu, Crescens, et al.
Publicado: (2020)

The impact of systemic precision medicine and immunotherapy treatments on brain metastases
por: Han, Rowland H., et al.
Publicado: (2019)

Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
por: Adamaki, Maria, et al.
Publicado: (2021)

Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics
por: Franco Machado, João, et al.
Publicado: (2018)

Immuno-oncology combinations: raising the tail of the survival curve
por: Harris, Samuel J., et al.
Publicado: (2016)

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
por: Jordan, Emma J., et al.
Publicado: (2018)

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes
por: Zeng, Zhiwei, et al.
Publicado: (2020)

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
por: Yap, Timothy A, et al.
Publicado: (2014)

Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma
por: Šamec, Neja, et al.
Publicado: (2020)

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
por: Zhao, Qijie, et al.
Publicado: (2021)

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
por: Valenti, Fabio, et al.
Publicado: (2021)

Is there room for allergen immunotherapy for the treatment of atopic dermatitis in the precision medicine era?
por: Pessina, Benedetta, et al.
Publicado: (2022)

Spherical nucleic acids-based nanoplatforms for tumor precision medicine and immunotherapy
por: Liu, Songbin, et al.
Publicado: (2023)

Update of early phase clinical trials in cancer immunotherapy
por: Lee, Dae Ho
Publicado: (2021)

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
por: Sundar, Raghav, et al.
Publicado: (2017)

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging
por: Duan, Heying, et al.
Publicado: (2022)

Precision Immunotherapy for Sepsis
por: Peters van Ton, Annemieke M., et al.
Publicado: (2018)

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy
por: Bedke, Jens, et al.
Publicado: (2013)

Precision regenerative medicine
por: Lightner, Amy L., et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine
por: Lee, Soo-Youn
Publicado: (2020)

Combining precision oncology and immunotherapy by targeting the MALT1 protease
por: Mempel, Thorsten R, et al.
Publicado: (2022)

Systems Medicine for Precise Targeting of Glioblastoma
por: Zeng, Jie, et al.
Publicado: (2023)

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
por: Basu, B., et al.
Publicado: (2012)

Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?
por: Mirza, Sheefa, et al.
Publicado: (2023)

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials
por: Hirakawa, Akihiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ausjk2m43djp7q0q6k81keei3o